{
    "nctId": "NCT00086957",
    "briefTitle": "Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer",
    "officialTitle": "Phase I/II Trial of ZD1839 (Iressa\u00ae), Trastuzumab (Herceptin\u00ae), and Docetaxel (Taxotere\u00ae) in Patients With erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "Number of Participants With at Least One Dose Limiting Toxicity in Phase I",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed adenocarcinoma of the breast\n\n  * Metastatic disease\n* HER-2/neu overexpression (3+ by immunohistochemistry OR 2+ by fluorescence in situ hybridization)\n* Measurable or evaluable disease\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Absolute granulocyte count \u2265 1,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* AST and ALT \\< 2.5 times upper limit of normal (ULN) (5.0 times ULN in the presence of liver metastases)\n* Bilirubin \\< 1.5 times ULN\n* No unstable or uncompensated hepatic disease\n\nRenal\n\n* Creatinine \\< 1.6 mg/dL\n* No unstable or uncompensated renal disease\n\nCardiovascular\n\n* LVEF \\> 45% by echocardiogram or MUGA\n* No prior New York Heart Association class I-IV heart disease\n* No prolonged PR interval or atrioventricular block on ECG\n* No unstable or uncompensated cardiac disease\n\nPulmonary\n\n* No unstable or uncompensated respiratory disease\n* No clinically active interstitial lung disease\n\n  * Patients who are asymptomatic and have chronic stable radiographic changes are allowed\n\nImmunologic\n\n* No autoimmune disorders\n* No conditions of immunosuppression\n* No severe hypersensitivity to taxane or gefitinib or any of its excipients\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other prior or concurrent malignancy within the past 5 years except basal cell carcinoma or carcinoma in situ of the cervix\n* No other severe or uncontrolled systemic disease\n* No other acute or chronic medical condition that would preclude study participation\n* No other significant clinical disorder or laboratory finding that would preclude study participation\n* No psychiatric illness that would preclude study compliance\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Prior adjuvant trastuzumab (Herceptin\u00ae) allowed if \\> 6 months elapsed before disease recurrence\n* No prior trastuzumab for metastatic breast cancer\n* No prior monoclonal antibodies directed at the epidermal growth factor receptor (EGFR)\n\nChemotherapy\n\n* Prior adjuvant chemotherapy (or as first-line therapy for metastatic breast cancer) allowed\n* Prior adjuvant taxane allowed if completed \\> 6 months before diagnosis of metastatic breast cancer\n* No prior docetaxel for metastatic breast cancer\n\nEndocrine therapy\n\n* Prior adjuvant hormonal therapy (or as first-line therapy for metastatic breast cancer) allowed\n* No concurrent hormonal therapy\n\n  * Concurrent steroids allowed provided dose is stable\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Fully recovered from prior oncologic or other major surgery\n* No concurrent surgery within 7 days of gefitinib administration\n\nOther\n\n* Recovered from prior anticancer therapy (alopecia allowed)\n* More than 30 days since prior non-approved drug or investigational agent\n* No other prior EGFR-directed therapy (i.e., tyrosine kinase inhibitors)\n* No concurrent use of any of the following medications:\n\n  * Phenytoin\n  * Carbamazepine\n  * Barbiturates\n  * Rifampin\n  * Hypericum perforatum (St. John's wort)\n* No other concurrent anticancer therapy\n* No concurrent cardioprotective drugs\n* No concurrent oral retinoids\n* Concurrent participation in the City of Hope indium-labeled trastuzumab imaging study allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}